Supply Chain Intelligence

Kura Oncology, Inc. Supply Chain

KURA supply chain intelligence for Kura Oncology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

KURA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
3Customers
3Debt Items
20Related Chains

Kura Oncology, Inc. Suppliers

TickerNameConfidenceEvidence
BMS BMS 90% Under the terms of the agreement, Mirati (now a BMS company) supplies us with adagrasib for the NSCLC, CRC and PDAC combin
MIRATI MIRATI 90% Under the terms of the agreement, Mirati (now a BMS company) supplies us with adagrasib for the NSCLC, CRC and PDAC combin
KYOWA-KIRIN KYOWA-KIRIN 80% Our collaboration with Kyowa Kirin is important to our business.
ALLR Allarity Therapeutics, Inc. 72% Reciprocal relationship from ALLR graph: Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipmen…
ATNM Actinium Pharmaceuticals, Inc. 72% Reciprocal relationship from ATNM graph: eferred to and treated in comprehensive treatment centers for in-patient treatment as opposed to community, outpatient-based care. As a result, we believe the…

Kura Oncology, Inc. Customers

TickerNameConfidenceEvidence
KYOWA-KIRIN-INC KYOWA-KIRIN-INC 92% We record all U.S. sales of KOMZIFTI, and we and Kyowa Kirin share equally the profits and losses from the commercialization activities in the United States.
KYOWA-KIRIN-CO-LTD KYOWA-KIRIN-CO-LTD 85% cial to patients who are often elderly and on several concomitant medications. We initiated commercial sales of KOMZIFTI in the United States on November 21, 2025. Under the terms of the collaboratio…
ALLR Allarity Therapeutics, Inc. 72% Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the…

Kura Oncology, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
KURA-DEBT-10586 Xbrl Convertible 90% xbrl convertible detail from xbrl 2015-12-31.
KURA-DEBT Debt stack $24.3M 90% Market cache reports total debt of $24.3M.
KURA-DEBT-10585 Warrants outstanding: 294000 90% xbrl warrant detail from xbrl 2022-12-31.

Kura Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kura Oncology, Inc..

Kura Oncology, Inc. Ownership

HolderNameConfidenceEvidence
KURA-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 218 tracked holders.

Kura Oncology, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
OBIO Orchestra BioMed Holdings, Inc. 100.00 2
MDGL Madrigal Pharmaceuticals, Inc. 100.00 2
PHGE BiomX Inc. 100.00 2
SGHT Sight Sciences, Inc. 100.00 2
MAZE Maze Therapeutics, Inc. 100.00 2
SVRA Savara Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
ALLR Allarity Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
ALEC Alector, Inc. 100.00 2
CMPS COMPASS Pathways plc 100.00 2
REPL Replimune Group, Inc. 100.00 2
RCUS Arcus Biosciences, Inc. 100.00 2
VRDN Viridian Therapeutics, Inc. 100.00 2
ATNM Actinium Pharmaceuticals, Inc. 100.00 1 ['supplier']
BCYC Bicycle Therapeutics plc 100.00 2
ENGN enGene Therapeutics Inc. 100.00 2
IRON Disc Medicine, Inc. 100.00 2
AZN AstraZeneca PLC 50.00 2
REGN Regeneron Pharmaceuticals, Inc. 50.00 2
View KURA supply chain intel →

Explore the full interactive supply chain map for Kura Oncology, Inc..

Open KURA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map